

Supplementary

Table S1 Valve hemodynamic characteristics and pathophysiology

Variables	Overall (n=651)	Mitral valve (n=166)	Aortic valve (n=485)	P value
Aortic valve insufficiency				<0.001
None	97 (14.9)	45 (27.1)	52 (10.7)	
Trace	101 (15.5)	36 (21.7)	65 (13.4)	
Mild	154 (23.7)	32 (19.3)	122 (25.2)	
Moderate	117 (18.0)	16 (9.6)	101 (20.8)	
Severe	146 (22.4)	10 (6.0)	136 (28.0)	
Unknown	36 (5.5)	27 (16.3)	9 (1.9)	
Aortic valve stenosis	444 (68.2)	47 (28.3)	397 (81.9)	<0.001
Aortic valve etiology				0.107
Degenerative	557 (85.6)	142 (85.5)	415 (85.6)	
Endocarditis	21 (3.2)	3 (1.8)	18 (3.7)	
Rheumatic	17 (2.6)	7 (4.2)	10 (2.1)	
Primary aortic disease	10 (1.5)	0 (0.0)	10 (2.1)	
Other	46 (7.1)	14 (8.4)	32 (6.6)	
Bicuspid aortic valve	218 (33.5)	7 (4.2)	211 (43.5)	<0.001
Mitral valve insufficiency				<0.001
None	29 (4.5)	1 (0.6)	28 (5.8)	
Trace	175 (26.9)	8 (4.8)	167 (34.4)	
Mild	205 (31.5)	24 (14.5)	181 (37.3)	
Moderate	82 (12.6)	28 (16.9)	54 (11.1)	
Severe	124 (19.0)	104 (62.7)	20 (4.1)	
Not documented	36 (5.5)	1 (0.6)	35 (7.2)	
Mitral valve stenosis	116 (17.8)	101 (60.8)	15 (3.1)	<0.001
Mitral valve etiology				<0.001
Degenerative	298 (45.8)	58 (34.9)	240 (49.5)	
Endocarditis	8 (1.2)	7 (4.2)	1 (0.2)	
Rheumatic	149 (22.9)	60 (36.1)	89 (18.4)	
Ischemic	76 (11.7)	25 (15.1)	51 (10.5)	
Congenital	1 (0.2)	1 (0.6)	0 (0.0)	
Other	119 (18.3)	15 (9.0)	104 (21.4)	

Data are shown as number (percentage).

Table S2 Outcomes in patients who survived at least 1-year following the index operation, stratified by anticoagulation

Variables	Overall (n=622)	Non-therapeutic (n=299)	Therapeutic (n=323)	P value
Death	31 (5.0)	15 (5.0)	16 (5.0)	0.971
Readmission	282 (45.3)	152 (50.8)	130 (40.3)	0.008
Heart failure readmission	113 (18.2)	69 (23.1)	44 (13.6)	0.002
Hemorrhagic stroke	11 (1.8)	6 (2.0)	5 (1.6)	0.665
Ischemic stroke	27 (4.3)	18 (6.0)	9 (2.8)	0.048
Transient ischemic attack	4 (0.6)	2 (0.7)	2 (0.6)	0.938
Bleeding event	4 (0.6)	3 (1.0)	1 (0.3)	0.280
Non-stroke thromboembolism	3 (0.5)	2 (0.7)	1 (0.3)	0.518
Readmission for heparin	96 (15.4)	56 (18.7)	40 (12.4)	0.029

Data are shown as number (percentage).

Table S3 Post-operative outcomes in the non-therapeutic and therapeutic groups, stratified by valve position

Variables	Non-therapeutic	Therapeutic	P value
Mitral valve	N=122	N=43	
Mortality	18 (14.75)	5 (11.63)	0.61
Any readmission	75 (61.48)	20 (46.51)	0.09
Readmission category			
Heart failure	49 (40.16)	11 (25.58)	0.09
Hemorrhagic stroke	5 (4.10)	1 (2.33)	0.59
Ischemic stroke	8 (6.56)	3 (6.98)	0.92
Transient ischemic attack	2 (1.64)	0 (0.00)	0.40
Bleeding	3 (2.46)	0 (0.00)	0.30
Thromboembolism	1 (0.82)	0 (0.00)	0.55
Need for heparin	32 (26.23)	5 (11.63)	0.05
Aortic valve	N=196	N=286	
Mortality	16 (8.16)	17 (5.94)	0.34
Any readmission	88 (44.90)	113 (39.51)	0.24
Readmission category			
Heart failure	25 (12.76)	36 (12.59)	0.96
Hemorrhagic stroke	3 (1.53)	4 (1.40)	1.00
Ischemic stroke	11 (5.61)	7 (2.45)	0.09
Transient ischemic attack	0 (0.00)	2 (0.70)	0.70
Bleeding	1 (0.51)	1 (0.35)	1.00
Thromboembolism	1 (0.51)	1 (0.35)	1.00
Need for heparin	32 (16.33)	35 (12.24)	0.02

Data are shown as number (percentage).




Figure S1 Freedom from readmission for IV heparin in patients classified as non-therapeutic or therapeutic based on number of INR levels within the therapeutic range. HRs for the non-therapeutic INR group with associated 95% CIs and P values are shown in the table in the inset. IV, intravenous; INR, international normalized ratio; HR, hazard ratio; CI, confidence interval.




Figure S2 Freedom from non-stroke peripheral arterial thromboembolism (A) and major bleeding (B) in patients classified as non-therapeutic or therapeutic based on number of INR levels within the therapeutic range. INR, international normalized ratio.